IPO Amount: $50M
Date: August 5
Range: $14 to $16
Actual price: $10

Scoop: Initially, NuPathe had hoped for $14-$16 per share; however, the Conshohocken, PA-based company had to cut its IPO price to just $10 a share. NuPathe's has a migraine treatment called Zelrix, which has completed Phase III testing. The trial showed that migraine symptoms like pain, nausea and sensitivity to light and sound, significantly improved two hours after applying the Zelrix patch. Just this month, the company reported the FDA had accepted its NDA for Zelrix. And the company expects to receive a PDUFA date of Aug. 29. Zelrix is the first ever submission to the FDA of a transdermal patch for the treatment of migraine.